SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-369138
Filing Date
2021-12-29
Accepted
2021-12-29 16:11:53
Documents
13
Period of Report
2021-12-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d279163d8k.htm   iXBRL 8-K 23931
2 EX-10.1 d279163dex101.htm EX-10.1 8732
  Complete submission text file 0001193125-21-369138.txt   153450

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20211224.xsd EX-101.SCH 2934
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20211224_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20211224_pre.xml EX-101.PRE 10981
7 EXTRACTED XBRL INSTANCE DOCUMENT d279163d8k_htm.xml XML 3214
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 211528998
SIC: 2834 Pharmaceutical Preparations